Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mallinckrodt divests BioVectra for $250mm as it focuses on specialty brands

Executive Summary

As part of its efforts to refocus on branded products, Mallinckrodt PLC divested its contract research division BioVectra Inc. to an affiliate of private equity firm HIG Capital for $135mm up front, a $40mm long-term note, and $75mm in earn-outs.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Liposomes
    • Nanotechnology, Chips, etc.
    • Synthesis Technologies, Production Processes
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
Deal Status
  • Final
Deal Type
  • Acquisition
    • Buy-out
    • Divestiture/Spin-Out
    • Payment Includes Cash
    • Full Acquisition
    • Includes Earnout

Related Companies